DCP 001

Drug Profile

DCP 001

Latest Information Update: 23 Sep 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator DCPrime
  • Class Cancer vaccines; Dendritic cell vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Acute myeloid leukaemia
  • Preclinical Multiple myeloma

Most Recent Events

  • 23 Sep 2015 Clinical development for Acute myeloid leukaemia is ongoing
  • 28 May 2013 DCPrime completes a phase I/II trial in Acute myeloid leukaemia in Netherlands (NCT01373515)
  • 01 Feb 2012 Acute myeloid leukaemia vaccine - DCPrime receives Orphan Drug status for Acute myeloid leukaemia in European Union
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top